1160 related articles for article (PubMed ID: 31088482)
41. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
42. Targeting a cell state common to triple-negative breast cancers.
Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
[TBL] [Abstract][Full Text] [Related]
43. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
[TBL] [Abstract][Full Text] [Related]
44. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
Li W; Yang H; Li X; Han L; Xu N; Shi A
Oncol Rep; 2019 Jan; 41(1):437-446. PubMed ID: 30365081
[TBL] [Abstract][Full Text] [Related]
45. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
47. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
48. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
49. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
50. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
51. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
52. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
53. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
[TBL] [Abstract][Full Text] [Related]
54. Role of STAT3 signaling pathway in breast cancer.
Ma JH; Qin L; Li X
Cell Commun Signal; 2020 Feb; 18(1):33. PubMed ID: 32111215
[TBL] [Abstract][Full Text] [Related]
55. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
56. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
[TBL] [Abstract][Full Text] [Related]
57. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
58. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
[TBL] [Abstract][Full Text] [Related]
59. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
60. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]